Introduction {#Sec1}
============

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia has spread rapidly in China and soon after around the world. It has been declared by WHO as a global public health emergency and named as Coronavirus disease 2019 (COVID-19) on January 13, 2020 (Huang *et al.*[@CR5]; Zhou *et al*. [@CR23]; Zhu *et al.*[@CR24]). As of July 08, 2020, there have been about 11,669,259 confirmed cases, and 539,906 deaths caused by the COVID-19 (WHO [@CR15]).

The clinical spectrum of patients with COVID-19 varies from asymptomatic infection, mild discomfort to severe viral pneumonia with respiratory failure and even death (Chen *et al.*[@CR3]; Wang *et al.*[@CR14]). The symptoms and clinical features of patients with COVID-19 include lower respiratory tract illness with fever, dry cough and dyspnea. These symptoms are similar to those of two other diseases caused by coronaviruses: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) (Tsang *et al*. [@CR13]; Assiri *et al*. [@CR1]).

Prompt and accurate diagnosis is the first and vital step to effectively control the ongoing outbreak of emerging COVID-19 epidemics (Sridhar *et al.*[@CR11]; Yang *et al.*[@CR18]). The radiological characteristics of patients with COVID-19 pneumonia are diverse, from nondistinctive features, diffuse changes, to destruction of the pulmonary parenchyma (Shi *et al.*[@CR10]). However, the evidences based on radiological characteristics alone are not sufficient to confirm the virus. One commonly accepted clinical method in confirming infected cases of COVID-19 is based on detection of unique sequences of virus RNA via quantitative reverse transcriptase polymerase-chain-reaction (qRT-PCR), which has the advantages of high-accuracy and high specificity.

However, there is still a possibility that false-negative results might occur due to the low viral loads of the samples (To *et al.*[@CR12]; Zou *et al.*[@CR25]). Measurement of anti-SARS-CoV-2 antibodies theoretically could remedy the detection of nucleic acid and be used for retrospective diagnosis and contact tracing. Therefore, in the present study, we retrospectively analyzed the sensitivities and dynamics of IgG and IgM antibodies detected by ELISA in COVID-19 patients at early stage of outbreak in Wuhan, as to provide early diagnosis information in this field.

Materials and Methods {#Sec2}
=====================

Study Design and Participants {#Sec3}
-----------------------------

This single-center, retrospective study was conducted at Jin-Yin-Tan Hospital (Wuhan, China), which is a designated hospital to treat COVID-19 patients. We recruited 131 patients who had been diagnosed with COVID-19 before 15 January 2020. According to WHO interim guidance, at least one-time antibody detection was done during their hospitalization (WHO [@CR16]).

Serological Tests for Anti-SARS-CoV-2 Antibodies {#Sec4}
------------------------------------------------

Anti-SARS-CoV-2 IgG and IgM antibodies in serum samples of COVID-19 patients were detected with the serological methods as reported previously, which showed no cross-reactivity with other commonly circulating human coronaviruses (e.g. HCoV-OC43) (Kissler *et al.*[@CR6]). In-house anti-SARS-CoV-2 IgG and IgM ELISA kits were developed using SARSr-CoV Rp3 nucleocapsid protein (NP) as antigen, which is \> 90% amino acid identity compared to reported SARSr-CoVs (Wang *et al.*[@CR26]; Zhou *et al*. [@CR22]). For IgG test, MaxiSorp Nunc-immuno 96 well ELISA plates were coated with 100 ng/well of recombinant NP overnight, then incubated with human sera in duplicates at a dilution of 1:20 for an hour at 37 °C, and followed by detection with anti-Human IgG-HRP conjugated monoclonal antibody (Kyab Biotech Co., Ltd, Wuhan, China) at a dilution of 1:40,000. For IgM test, MaxiSorp Nunc-immuno 96 well ELISA plates were coated with 500 ng/well anti-human IgM (µ chain) overnight, then incubated with human sera in duplicates at 1:100 dilution for 40 min at 37 °C, and followed by detection with anti-Rp3 NP-HRP conjugated antibody (Kyab Biotech Co., Ltd, Wuhan, China) at a dilution of 1:4000. The OD values of 450--630 nm were calculated. 240 random negative control samples and two SARS-CoV-2 positive control samples were used to set the cutoff values of IgG and IgM. According to the Kit instruction, we used the mean OD value of the negative control samples plus three standard deviations to set the cutoff values of IgG and IgM at 0.143 and 0.142, respectively. The specificity of these positive samples was confirmed by Western blot with recombinant Rp3 NP.

Collection of Clinical Data and Evaluation of Chest CT {#Sec5}
------------------------------------------------------

All the clinical data on epidemiology, including exposure history, symptoms, underlying comorbidities and laboratory results were retrospectively extracted from electronic medical records. The date of disease onset was defined as the day when the symptom was noticed. All CT images were reviewed by two experienced radiologists, and decisions were reached by consensus agreement.

Statistical Methods {#Sec6}
-------------------

All statistical analyses were performed with SPSS software (version 20.0, IBM, Armonk, NY). Continuous normally distributed variables were presented as $\documentclass[12pt]{minimal}
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                \begin{document}$$\bar{x}$$\end{document}$ ± SD, non-normally distributed data and categorical variables are shown as frequencies and percentages. Statistical analyses were done by one-way analysis of variance (ANOVA) for numerical data and Chi Square Test for multiple comparisons of categorical data. *P* value of less than 0.05 was considered statistically significant.

Results {#Sec7}
=======

Clinical Characteristics {#Sec8}
------------------------

Table [1](#Tab1){ref-type="table"} presents the demographic and clinical characteristics of the 131 confirmed cases (69% male, 31% female), who were admitted to Jin-Yin-Tan Hospital between 30 December, 2019 and 15 January, 2020 with mean 9 (± 3.9) days after onset of symptom. The average age was 51.4 (± 11.8) years and 17.5% patients were older than 60. All patients were residents of Wuhan or surrounding areas. 75 (57%) patients had a history of exposure to the Huanan Seafood Market, 12 (9%) cases had exposure to patients with confirmed or highly suspected COVID-19, and 9 (7%) patients were clustered onset. Among those 131 patients, 55 (42%) had underlying chronic diseases, including 31 (24%) hypertension, 14 (11%) diabetes and 7 (5%) with chronic heart disease.Table 1Demographics and clinical characteristics of the included patients.Clinical characteristics(n = 131)Sex (Male/Female)90 (68.7%)/41 (31.3%)Age, years51.4 ± 11.8 (24--81)Age range, years 24--3919 (14.5%) 40--5976 (58.0%) 60--7935 (16.7%) ≥ 801 (0.8%)Days from onset to hospitalization9.04 ± 3.93 (1--24)Time of staying in hospital (days)18.26 ± 10.06 (4--72)Normal/severe/critical cases15 (11.4%)/82 (62.6%)/34 (26.0%)Comorbidities55 (42%) Hypertension31 (23.7%) Diabetes mellitus14 (10.7%) Heart disease7 (5.3%)Epidemiologic history History of residence or travel131 (100%) Exposure to Huanan Seafood Wholesale Market75 (57.3%) History of contacting with COVID-19 patients12 (9.2%) Clustered onset9 (6.9%)Onset symptoms Fever124 (94.7%) Cough96 (73.3%) Dyspnea50 (38.2%) Fatigue43 (32.8%) Shortness of breath33 (25.2%) Gasping22 (16.8%) Muscle ache20 (15.3%) Headache15 (11.5%) Chill12 (9.2%) Chest pain7 (5.3%) Nausea5 (3.8%) Dizziness5 (3.8%) Sore throat4 (3.1%) Runny nose4 (3.1%) Difficulty breathing4 (3.1%) Joint soreness4 (3.1%) Palpitations3 (2.3%) Vomit3 (2.3%) Shivering3 (2.3%) Diarrhea2 (1.5%)Treatment Glucocorticoids64 (48.9%) Immunoglobulin19 (14.5%) High-flow Nasal Cannula33 (25.2%) Non-invasive ventilation16 (12.2%) Invasive ventilation7 (5.3%) Extracorporeal membrane oxygenation4 (3.1%) Renal replacement therapy6 (4.6%) Blood transfusion4 (3.1%) Vasoconstrictive agents4 (3.1%)Complication72 (55.0%) Liver dysfunction48 (36.6%) Acute respiratory distress syndrome40 (30.5%) Hypoproteinemia34 (26.0%) Sepsis18 (13.7%) Thrombocytopenia16 (12.2%) Acute kidney injury13 (9.9%) Septic shock11 (8.4%) Acute myocardial injury9 (6.9%)In-hospital mortality15 (11.5%)

The most common symptoms at admission were fever (124, 94.7%), cough (96, 73.3%) and dyspnea (50, 38.2%). A few patients presented atypical onset symptoms, including headache (15, 12%), dizziness (5, 4%), nausea (5, 4%), vomit (3, 2%) and diarrhea (2, 1.5%). Almost half of the patients (64, 49%) received glucocorticoids, 19 (14.5%) cases received human immunoglobulin; 33 (25.5%) patients were treated with high-flow nasal cannula, 23 (17.6%) with mechanical ventilation, 4 (3.1%) with extracorporeal membrane oxygenation (ECMO), 6 (4.6%) with renal replacement therapy, and 4 (3.1%) with vasoconstrictive agents.

More than half (72, 55.5%) of the patients had damage in organ function, including 48 (36.6%) with liver dysfunction, 40 (30.5%) with ARDS, 13 (9.9%) with acute kidney injury, 11 (8.4%) with septic shock, and 9 (6.9%) with acute cardiac injury. Most of the patients (82, 62.6%) were severe cases and a quarter of patients were critical cases according to the clinical classification defined by General Office of National Health Committee of China (General Office of National Health Committee [@CR4]). Fifteen (11.5%) of those patients died during hospitalization (Table [1](#Tab1){ref-type="table"}).

Laboratory Parameters {#Sec9}
---------------------

The majority of the patients had a normal white blood cell count (88/131, 67.2%) and normal procalcitonin (123/128, 96.1%). More than half of the patients had a reduced lymphocyte count (83/131, 63.4%), and increased indicators of inflammation, including ESR (120/127, 94.5%), C-reactive protein (107/128, 83.6%), interleukin 6 (49/97, 50.5%), LDH (85/128, 66.4%) and ferritin (86/119, 72.3%). Some patients showed abnormal coagulation function index, including increased fibrinogen (92/124, 74.2%) and increased D-Dimer (20/123, 16.3%) (Table [2](#Tab2){ref-type="table"}).Table 2Laboratory parameters.ParameterWhite blood cell count, × 10^9^/L6.02 ± 3.30 \< 3.525/131 (19.1%) 3.5 \~ 9.588/131 (67.2%) \> 9.518/131 (13.7%)Neutrophil count, × 10^9^ /L4.66 ± 3.38Lymphocyte count, × 10^9^ /L1.00 ± 0.52 \< 1.183/131 (63.4%) ≥ 1.148/131 (36.6%)C-reactive protein, mg/L \< 521/128 (16.4%) ≥ 5107/128 (83.6%)Procalcitonin, ng/mL \< 0.5123/128 (96.1%) ≥ 0.55/128 (3.9%) ESR, mm/h49.82 ± 5.06 \< 157/127 (5.5%) ≥ 15120/127 (94.5%) Interleukin6, pg/mL8.10 ± 5.80 \< 748/97 (49.5%) ≥ 749/97 (50.5%)Ferritin, ng/mL \< 274.6633/119 (27.7%) ≥ 274.6686/119 (72.3%) LDH, mmol/L326.14 ± 113.74 \< 25043/128 (33.6%) ≥ 25085/128 (66.4%) FIB, g/L5.26 ± 1.91 \< 23/124 (2.4%) 2 \~ 429/124 (23.4%) ≥ 492/124 (74.2%)D-Dimer, mg/L \< 1.5103/123 (83.7%) ≥ 1.520/123 (16.3%)Continuous data are expressed as mean ± SD. Categorical data are presented as n/N (%), where N is the total number of patients with available data.

CT Image Acquisition {#Sec10}
--------------------

All patients had been chest CT scanned at outpatients department or at other hospitals before admission. All of them were reported with lung infection and, most likely, the viral pneumonia. 124 cases were re-conducted chest CT scan during hospitalization after 15 (± 5.4) days from onset. All chest CT images showed abnormalities, ground glass opacity and infiltrates shadows or consolidation. The majority of the patients presented bilateral, multifocal lung lesions, with peripheral distribution. Pleural effusion were uncommon imaging findings in those patients.

Sensitivity of IgM and IgG ELISA Detection in COVID-19 Patients {#Sec11}
---------------------------------------------------------------

The sensitivities of the IgG and IgM ELISA detection in serum samples obtained from patients at different periods after disease onset are shown in Table [3](#Tab3){ref-type="table"}. The overall sensitivities of IgG ELISA (92.5%) were significantly higher than that of IgM ELISA (70.8%) (*P* \< 0.001). In addition, the sensitivity of IgG ELISA in different periods after disease onset (5--10, 11--20 and 31--40 days) were generally higher than that of IgM ELISA, except for the equivalent from 31 to 40 days (*P* \> 0.05) (Table [3](#Tab3){ref-type="table"}). The mean OD450 values of IgM and IgG for 226 serum samples obtained from the 131 confirmed COVID-19 cases were 0.391 and 1.565, with standard deviations of 0.496 and 0.722 respectively (Table [3](#Tab3){ref-type="table"}). For IgG, the mean OD450 values significantly increased to 1.683 during 11 to 20 days after onset, and then maintained relatively high (Table [3](#Tab3){ref-type="table"}). For IgM, however, the OD450 values reached the peak of 0.435 during 21 to 30 days after onset and fell back to 0.187 during 31 to 40 days after onset (Table [3](#Tab3){ref-type="table"}). The sensitivity of IgM increased if the samples were re-detected (Table [4](#Tab4){ref-type="table"}).Table 3Differential sensitivity of ELISA for detection of IgM and IgG in different periods after disease onset.Days after onsetNumber of samplesNumber of positive for IgM by ELISANumber of positive for IgG by ELISAELISA OD ratio of IgMELISA OD ratio of IgG5 \~ 103413 (38.2%)22 (64.7%)\*0.202 ± 0.2730.905 ± 0.80811 \~ 20151115 (76.2%)147 (97.4%)\*0.431 ± 0.5341.683 ± 0.653^\#^21 \~ 303528 (80.0%)35 (100%)\*0.435 ± 0.4931.686 ± 0.542^\#^31 \~ 4064 (66.7%)5 (83.3%)0.187 ± 0.1031.621 ± 0.932^\#^5 \~ 40226160 (70.8%)209 (92.5%)\*0.391 ± 0.4961.565 ± 0.722^\#^\**P* \< 0.05 versus IgM in the same period.^\#^*P* \< 0.05 versus 5 to 10 days.Table 4Differential sensitivity of ELISA for detection of IgM and IgG with different times in COVID-19 patients.Times of detectionNumber of patientsNumber of positive for IgM by ELISANumber of positive for IgG by ELISA13626 (72.2%)35 (97.2%)29587 (91.6%)\*94 (98.9%)Total131113 (86.3%)129 (98.5%)\**P* \< 0.05 versus once.

Dynamic Changes of IgG and IgM Antibodies for COVID-19 Patients {#Sec12}
---------------------------------------------------------------

Among the 131 confirmed cases, 16 cases were in hospital varying 30 to 60 days after onset of illness, whereas 109 patients were discharged within 30 days after onset. 115 patients survived. The median OD450 results from the available serum specimens of all patients were calculated and were plotted as a function of the days from onset of symptoms (Fig. [1](#Fig1){ref-type="fig"}). For IgM, the median OD450 rose above the baseline level at day 6 (seroconversion time), peaked at around day 18, and fell to below the baseline level at about day 36. The seroconversion time of IgG was 3 days. The IgG antibody level peaked at around 23 days, and then maintained relatively high (Fig. [1](#Fig1){ref-type="fig"}). IgG antibodies in 3 of 95 patients converted from positive to negative after 5 days (detected twice) (Table [5](#Tab5){ref-type="table"}). Two of these three patients had only mild symptom but the third one presented critical situation and later died in hospital.Fig. 1Longitudinal profile of IgG and IgM antibodies in 131 patients with COVID-19.Table 5Dynamic changes of IgM and IgG in COVID-19 patients (n = 95).Negative to positivePositive to negativePositive twiceNegative twiceNumber (%) of IgM change30 (31.6%)10 (10.5%)47 (49.5%)8 (8.4%)Number (%) of IgG change11 (11.6%)3 (3.2%)80 (84.1%)1 (1.1%)

Discussion {#Sec13}
==========

Being able to detect the virus promptly and accurately is crucial in curbing the wide spread of infectious diseases, such as the COVID-19 which spread rapidly and killed a lot of people. Generally, the testing methods are based on the epidemiological risk, clinical features, imaging features and laboratory assays. We reported the retrospective sensitivity comparison of IgM and IgG ELISA detection for 131 confirmed cases of COVID-19 at early stage of outbreak in Wuhan. Meanwhile, the clinical characteristics of abovementioned patients were collected and analyzed. Over half of the patients in our study were male and had a history of exposure to the Huanan Seafood Market. The clinical features of fever, dry cough and dyspnea, which were in general the typical respiratory symptom and similar to SARS-CoV and MERS-CoV infections (Assiri *et al.*[@CR1]), were respectively observed among 94.7%, 73.3% and 38.2% of the total 131 confirmed cases. However, a few patients presented common atypical onset symptoms, including headache, dizziness, nausea, vomit or diarrhea, which were unique and might lead to misdiagnosis. Moreover, since COVID-19 patients may harbor the virus in the intestine at the early or late stage of infection (Zhang *et al.*[@CR19]), the suspected cases who mainly presented intestinal signs and symptoms were suggested to have a test with SARS-CoV-2 nucleic acid from faecal samples or anal swabs.

Among the total investigated cases, 55.5% of them suffered from organ function damage, and 63.4% of them showed common symptoms on reduced lymphocyte count and increased indicators of inflammation. These are all indicators of critical illness and poor prognosis (Yang *et al.*[@CR18]; Zhao *et al*. [@CR20]). The majority of the patients had a normal white blood cell count (67.2% of patients) and normal procalcitonin (92.1% of patients), which was consistent with rare bacterial infection. Unfortunately, 16 cases (12%) developed severe illness and eventually died.

The sensitivity of IgG was significantly higher than that of IgM in this work, which is consistent with the results from recent reports (Long *et al.*[@CR8]; Qu *et al.*[@CR9]; Xiang *et al*. [@CR17]; Zhao *et al*. [@CR20]), where IgG tests performed 100% of sensitivity. The seroconversion of IgG against SARS-CoV-2 was earlier than that of IgM (3 days vs 6 days after onset), then maintained at high level longer than IgM. IgG maintained positive longer than 50 days, but IgM converted to negative around 36 days after onset. This observation is significantly different with dynamic changes of antibodies against SARS-CoV reported previously (Chan *et al.*[@CR2]).

As we observed, IgG antibody could generally keep positive for a long period. While a surprising observation is that 3 cases converted from positive to negative after 5 days with twice tests. It is still unclear whether the COVID-19 patients would acquire permanent immunity to this disease after certain time. Further studies are needed to confirm this.

In conclusion, our findings suggested that detection of antibodies showed tremendous value in helping diagnosis of COVID-19 infection. IgG could be a sensitive indicator for retrospective diagnosis and contact tracing, and IgM could be an indicator of early COVID-19.
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